The National Mesothelioma Audit (NMA) is commissioned and funded by Mesothelioma UK, a charity that provides specialist mesothelioma information and improved care.
What we are doing
Following the extension of the contract with Mesothelioma UK, from April 2018 to March 2020, the NMA will be producing two more reports to raise the profile of this asbestos-related cancer and to make recommendations to improve outcomes for mesothelioma patients.
There are four main aims for the mesothelioma audit:
- maintain and enhance the profile of mesothelioma, a disease with poor outcome and variation in care
- build upon the recommendations of the previous mesothelioma report and allow organisations to measure and demonstrate improvement over time
- embed a process of data collection for mesothelioma in clinical teams linked to an infrastructure that has a robust long-term future
- set new standards for mesothelioma.
What is mesothelioma?
Mesothelioma is a form of cancer that specifically affects the mesothelium, a thin membrane that lines the inner surface of the chest wall (pleura). Due to the relative rarity of mesothelioma compared to other lung cancers – approximately 2,500 people per year are diagnosed in the UK – mesothelioma did not receive adequate prominence in the overall NLCA report, but now features in this bespoke publication with collaboration and funding from Mesothelioma UK.